Crystal structure of the antimicrobial peptidase lysostaphin from *Staphylococcus simulans*

Izabela Sabala, Elzbieta Jagielska, Philip T. Bardelang, Honorata Czapinska, Sven O. Dahms, Jason A. Sharpe, Richard James, Manuel E. Than, Neil R. Thomas and Matthias Bochtler

1 International Institute of Molecular and Cell Biology, Warsaw, Poland
2 Centre for Biomolecular Sciences, School of Chemistry, The University of Nottingham, UK
3 Centre for Biomolecular Sciences, School of Molecular Medical Sciences, The University of Nottingham, UK
4 Leibniz Institute for Age Research – Fritz Lipmann Institute (FLI), Jena, Germany
5 Institute of Biochemistry and Biophysics, Polish Academy of Sciences, Warsaw, Poland

**Keywords**
crystal structure; lysis; lysostaphin; *Staphylococcus aureus*; *Staphylococcus simulans*

**Correspondence**
M. Bochtler, International Institute of Molecular and Cell Biology, Trojdena 4, 02-109 Warsaw, Poland
Fax: +48 225 970 715
Tel: +48 225 970 732
E-mail: mbochtler@iimcb.gov.pl

Elzbieta Jagielska and Philip T. Bardelang contributed equally to this work.

(Received 29 April 2014, revised 23 June 2014, accepted 11 July 2014)

doi:10.1111/febs.12929

**Structured digital abstract**
- lysostaphin by x-ray crystallography (1, 2).

**Introduction**

*Staphylococcus aureus* is a common human and animal pathogen of major clinical significance [1]. *Staphylococcus simulans* lysostaphin (EC 3.4.24.75) has staphyloytic properties that were originally discovered in the 1960s [2,3] and immediately attracted interest as a means of combating staphylococcal infection [4]. The topical or systemic use of lysostaphin has since proven effective in several mouse and rat models of staphylococcal infection [5,6]. Moreover, transgenic mice and cattle producing the enzyme have been generated to engineer *S. aureus* and/or *S. epidermidis* resistance [7,8], and adenovirus-mediated lysostaphin delivery has been tested in goats [9,10]. In humans, the protein has been effective in the experimental treatment of *S. aureus*-infected patients [11], and is currently in clinical trials for use in treating burns [12]. Lysostaphin has also shown promise for the elimination of *S. aureus* in infected asymptomatic carriers [13], which might be useful in a hospital setting. Apart from direct application in humans, lysostaphin has also been considered for the eradication of *S. aureus* biofilms from artificial surfaces [14] and as an antimicrobial agent in catheter coatings [15].

Lysostaphin is produced as a preproprotein (Uniprot entry P10547) with a leader sequence (residues...
1–23), inhibitory proregion (residues 24–247) [16], catalytic domain (residues 248–384), linker (residues 385–400) and cell-wall-targeting (CWT) domain (residues 401–493, UniProt numbering used throughout) (Fig. 1A). The latter three constitute the mature peptidase, henceforth termed ‘lysostaphin’. This cuts the peptide bond between the third and fourth glycine residues of the pentaglycine cross-link in the peptidoglycan (Fig. 1B) [17]. The active enzyme shares structurally characterized domains with LytM [18,19], Ale-1 [20] and LasA [21], but only the structure of mature lysostaphin can shed light on crucial aspects of the domain arrangement or substrate binding of this biotechnologically important enzyme.

Lysostaphin has many favorable properties (e.g. dependence of the enzyme activity on the ionic milieu compatible with in vivo applications) that are not shared by some of its homologues [22]. However, widespread use of lysostaphin has also identified its limitations. Staphylococcus aureus cells can acquire lysostaphin resistance by altering cross-bridges between peptidoglycan stem peptides [23]. A structure of lysostaphin might, therefore, be helpful in understanding its favorable properties, which could then be grafted onto homologues that do not share them (such as LytM [22]), as well as being used to generate variants of lysostaphin that overcome the limitations of the natural enzyme.

A crystal structure of lysostaphin has not yet been reported, despite widespread interest in the protein and the possible applicability of structural information. Here, we present a low-resolution (3.5 Å) structure of mature lysostaphin with catalytic and CWT domains, and two high-resolution (1.26 and 1.78 Å) crystal structures of the catalytic domain in isolation, which elucidate details of the active site architecture.

**Results and discussion**

**Crystallization and structure determination of mature lysostaphin**

Several differently tagged variants of mature lysostaphin (with catalytic and CWT domains, but without the proregion and leader peptide) were produced in the ectopic host *Escherichia coli* and purified by affinity chromatography and gel-filtration steps. The protein proved difficult to crystallize. Altogether, over 10 000 possible conditions were screened until diffracting crystals were obtained. Crystals diffracted to 3.5 Å and belonged to space group P4(3)32 with a large unit cell (282 Å length). Nevertheless, they contained only four molecules of lysostaphin in the asymmetric unit, which corresponds to > 85% solvent content (observed for only 0.05% of other crystals in the PDB). In retrospect, the large solvent content can be attributed to a highly unusual crystal packing. Although lysostaphin is a monomer in solution [24], pairs of lysostaphin molecules (adopting different conformations) assemble to form ‘heterodimers’. Because of a combination of local and crystallographic twofold symmetry, the original ‘heterodimers’ in turn form hollow, ball-like structures with 222-point symmetry, built of eight lysostaphin molecules (Fig. 2A). Although balls can, in principle, be packed very tightly (74% of space filled [25]), the assembly of balls in the lysostaphin crystals is characterized by large pores that are clearly visible in projections along the unit cell axes (Fig. 2B) and along the body diagonals (not shown). The phase problem for crystals of mature lysostaphin was solved using a combination of molecular replacement (search models based on deposited crystal structures of...
catalytic domain of LytM and CWT domain of Ale-1, respectively) and multiple anomalous diffraction (MAD) approaches. Data collection and refinement parameters are presented in Table 1.

Because multiple attempts to improve the diffraction limit of the mature lysostaphin crystals at synchrotrons (using annealing, dehydration, etc.) proved unsuccessful, we produced the catalytic domain in isolation, hoping that the globular nature of the domain would facilitate crystal packing. Indeed, crystals in space group \(P2(1)\) could be grown at similar pH in the presence and absence of phosphate. They diffracted to 1.26 and 1.78\(\AA\) resolution, respectively. The strongest diffracting crystals were pseudomerohedrally twinned with a twofold twinning axis along a face diagonal, made possible by the ‘coincidental’ equality of unit cell constants. Both structures could be readily solved by molecular replacement. For refinement, test reflections were chosen in thin-resolution shells to avoid introducing correlations between reflections. Data collection and refinement statistics for both structures are summarized in Table 1.

**Overall lysostaphin structure**

The crystal structure shows the expected overall organization of lysostaphin into an N-terminal catalytic domain and a C-terminal CWT domain (Fig. 3). When superimposed separately, the domains of the four molecules in the asymmetric unit of the mature lysostaphin crystals overlap very well, which may in part reflect the use of noncrystallographic symmetry restraints necessary at this resolution. However, we also observe essentially the same conformation in the crystals of the catalytic domain in isolation, suggesting that, at least, the structure of this domain is robust to changes in buffer composition. Amino acid conservation scores among selected sequences of catalytic and CWT domains from various *Staphylococci* and their bacteriophages, showing up to 45% sequence identity to lysostaphin were mapped to the surface of its domains and are high in the region of the active site, and also in the likely peptide-binding region of the CWT domain (Fig. 4A,B). The electrostatic surface of lysostaphin is a meshwork of regions of positive and negative potential, without large hydrophobic regions, consistent with either solvent exposure or binding to the pentaglycine peptide (containing multiple hydrogen bond donors and acceptors) (Fig. 4C).

**Catalytic domain**

The lysostaphin catalytic domain shares key features of the M23 family peptidases [27]. The core of these structures is an antiparallel \(\beta\) sheet that anchors the catalytic residues, which are grouped around a central \(\text{Zn}^{2+}\) cation (Fig. 5). Identification of this metal ion was confirmed crystallographically (by a drop in the anomalous density peak height at the metal ion sites passing from the absorption to the inflection point wavelength). In the high-resolution structures it is additionally supported by typical metal–ligand distances and similar temperature factors for the metal ion and the surrounding ligands. The \(\text{Zn}^{2+}\) ion is coordinated by His279 and Asp283 of the characteristic HxxD motif and His362 of the HxH motif of LAS peptidases, as expected.

---

**Fig. 2.** Crystal structure of mature lysostaphin. (A) Four crystallographically independent lysostaphin molecules (ribbon models) and their symmetry mates (behind them) form a hollow ‘ball’ of 222 point symmetry composed of altogether eight lysostaphin molecules (gray). The twofold symmetry axes are indicated as lines. (B) Packing of the ‘balls’ in (A) into the crystal lattice. The ‘face’ of the ball presented in (A) is turned towards the lower right-hand corner in (B).

**Fig. 3.** Domain mobility in full-length lysostaphin. Molecules in the asymmetric unit of the crystal are shown in ribbon representation, with the catalytic zinc ion shown as a ball. CWT (green) domains were superimposed. Catalytic domains (dark/light yellow and blue) differ in orientation by almost 100°.
The active site is located in a substrate-binding groove, as in other MEROPS M23 family proteins. The floor of the groove is built by the $\beta$ sheet of the protein and the walls are made up of loops L1–L4 as defined previously for LasA [21] and LytM [19]. The long L-shaped loop 1 is located above the Zn$^{2+}$ ion.

### Table 1. Data collection and refinement statistics

|                         | Full-length lysostaphin | Catalytic domain |
|-------------------------|-------------------------|-----------------|
| **Space group**         | MAD peak                | MAD IP          | Native$^a$ |
|                         | P4(3)32                 | P4(3)32         | P4(3)32    | P2(1)     | P2(1)     |
| **Cell dimensions**     |                         |                 |             |           |           |
| $a$ (Å)                 | 283.6                   | 283.3           | 282.0      | 34.3      | 34.3      |
| $b$ (Å)                 |                         |                 |             | 106.8     | 107.3     |
| $c$ (Å)                 |                         |                 |             | 34.3      | 34.3      |
| $\beta$ (°)             |                         |                 |             | 97.4      | 97.6      |
| **Beamline**            | DIAMOND IO2             | BESSY 14.1      | BESSY 14.1 | BESSY 14.2 |
| **Wavelength (Å)**      | 1.2827                  | 1.2832          | 0.9184     | 1.2000    | 0.9184    |
| **Resolution (Å)**      | 35–4.0                   | 35–4.0          | 50–3.5     | 50–1.26   | 35–1.78   |
| **Lowest shell**        | 35–17.85                | 35–17.84        | 50–15.65   | 50–3.76   | 35–5.28   |
| **Highest shell**       | 4.09–3.99               | 4.09–3.99       | 3.59–3.5   | 3.33–1.26 | 1.89–1.78 |
| $R_{\text{sym}}$ (%)$^b$| 28.5 (6.5, 54.2)         | 14.7 (3.2, 49.0)| 29.5 (5.1, 90.8)| 7.2 (5.6, 41.2)| 16.7 (5.7, 58.6)|
| $R_{\text{free}}$ (%)$^b$| 34.2 (7.8, 65.7)         | 17.6 (3.8, 58.9)| 30.0 (5.2, 92.0)| 7.8 (6.1, 46.6)| 21.3 (7.3, 73.0)|
| $CC_{1/2}$              | 93.8 (98.8, 77.7)        | 98.2 (99.8, 82.3)| 99.6 (100, 94.4)| 99.8 (99.7, 84.8)| 96.6 (99.1, 68.6)|
| $\langle|\sigma|^{2}\rangle$ | 5.6 (12.1, 2.8)         | 8.0 (18.5, 3.5) | 17.3 (57.0, 5.3) | 13.2 (30.8, 2.5) | 7.5 (17.0, 2.1) |
| Completeness (%)$^b$    | 96.3 (82.6, 97.8)        | 98.7 (82.3, 98.7)| 100.0 (100, 95.5)| 98.3 (99.8, 90.9)| 99.1 (97.1, 98.8)|
| Multiplicity$^b$        | 3.17 (3.30, 3.11)        | 3.22 (3.29, 3.22)| 36.4 (28.9, 37.9)| 5.8 (6.3, 4.5) | 2.7 (2.7, 2.7) |
| $V_M$                   | 8.3                      | 2.0             | 2.0        | 8.3       | 2.0       |
| Solvent content (%)     | 85.2                     | 39.6            | 39.9       | 85.2      | 39.6      |
| Twin law                | l,-k,h                   | l,-k,h$^d$      | l,-k,h$^d$ | l,-k,h$^d$ |
| Twin fraction (%)       | Estimated                | 37              | 22         | Estimated |
|                         | Refined                  | 36.0            | –          | Refined   |
| $<|E^2 - 1|>$            | 0.758                    | 0.776           | 0.746      | 0.622     | 0.700     |
| $<|L|>, <L^2>$          | 0.468, 0.296             | 0.493, 0.323    | 0.488, 0.317| 0.409, 0.232| 0.459, 0.283|
| **Refinement statistics**|                         |                 |             |           |           |
| Resolution              | 50–3.5                   | 35–1.26         | 35–1.78    | 35–1.78   |           |
| Highest shell (Å)       | 3.59–3.5                 | 1.30–1.27$^c$   | 1.88–1.78$^c$ |           |           |
| No. reflections         | 48 689                   | 64 902          | 23 369     |           |           |
| $R_{\text{work}}, R_{\text{free}}$ | 26.8/28.7               | 13.0/17.5       | 21.0/24.4  |           |           |
| Highest shell           | 30.4/35.6                | 20.9/30.7       | 32.1/33.3  |           |           |
| No. atoms$^e$           | 7589                     | 2495 (2328)     | 2378 (2325)|           |           |
| Protein                 | 7540                     | 2251 (2086)     | 2135 (2082)|           |           |
| Ligand/ion              | 49                       | 40              | 6          |           |           |
| Solvent                 | 0                        | 220 (218)       | 237        |           |           |
| Rmsd                    | Bond lengths (Å)         | 0.009           | 0.010      | 0.023     |           |
| Bond angles (°)         | 1.2                      | 1.2             | 1.8        |           |           |
| Ramachandran            | Allowed region (%)       | 100.0           | 100.0      | 100.0     |           |
|                         | Favored region (%)       | 93.56           | 97.5       | 97.4      |           |
| Molprobity clashscore   | 6                        | 3.6             | 4.1        |           |           |

$^a$ The native data contain Zn$^{2+}$ anomalous scatterers, but have been collected at a wavelength remote from the absorption peak.

$^b$ Data for the lowest and highest resolution shells are shown in parentheses. The completeness for the data for the lowest shell and full resolution is calculated versus the number of possible reflections from infinity to the stated high-resolution limit.

$^c$ Data for the highest resolution shells are shown in parentheses.

$^d$ The twin component was not substantial enough to be used in the refinement (not to reduce the data to parameter ratio).

$^e$ Alternative conformations counted separately (the true number of atoms is shown in parentheses).

$^f$ Shells adjusted so that they include an $R_{\text{free}}$ reflection shell.
forming a roof above the active site oriented towards the middle of the groove. This loop and loops 3 and 4 have fairly similar conformations in all lysostaphin molecules in the three crystal forms. By contrast, the smaller loop 2 seems to be the most flexible (Fig. 6).

Zn$^{2+}$ coordination cannot be deduced with confidence for the mature lysostaphin structure, because of the limited resolution. Metal–ligand distance restrictions had to be imposed so that the zinc density does not dominate the positions of the lighter atoms. In one subunit, we tentatively modeled a sulfate ion (from the buffer) directly coordinating the Zn$^{2+}$ ion. By contrast, the structures of the catalytic domain are very informative in this respect. In crystals grown in the absence of phosphate ions, we observed a hexa-coordinated Zn$^{2+}$ ion in the active site, with the expected three amino acid ligands (His279, Asp283 and His362) and three water molecules, in a nearly perfect octahedral arrangement. In crystals grown in the presence of phosphate, the Zn$^{2+}$ amino acid ligands are arranged similarly, but instead of the water molecules, a phosphate ion is directly coordinated to the Zn$^{2+}$ ion. Two of the phosphate oxygen atoms are roughly in the positions previously occupied by water molecules (although the oxygen–oxygen distance is shorter for the phosphate than for the two water molecule oxygens). Such coordination is not unusual for Zn$^{2+}$ coordination by bidentate ligand atoms [28], and has also been described for LytM [19] (Fig. 5).

Tetracoordination of the Zn$^{2+}$ ion is typical for most LAS enzyme crystal structures, but the Zn$^{2+}$ ion in LasA from P. aeruginosa is pentacoordinated [21]. Pentacoordination is consistent with many proposals for catalytic mechanism, and also with EPR data for a Co$^{2+}$-substituted VanX (an enzyme that belongs to the LAS superfamily, but not to metallopeptidase clan M23) [29]. To our knowledge, hexacoordination with only amino acid and water (hydroxide) ligands has so far not been observed for any other LAS enzyme. Differences in coordination state may reflect variations between LAS family members, but more likely they simply reflect the low energy barriers for changes of Zn$^{2+}$ coordination [30], which may also play a role in catalysis [31].

**CWT domain**

The CWT domain of lysostaphin is highly similar in sequence (≥ 80% identity) and structure to the CWT of Ale-1 [20] (main chain atom rmsd 0.5 Å). Biochemical and structural studies indicate that this domain interacts directly with interpeptide bridges present in peptidoglycans [32]. The fold classifies the domain as SH3b, the prokaryotic counterpart of the eukaryotic SH3 domain [33]. At present, structural information

---

**Fig. 4.** Sequence conservation and electrostatics of lysostaphin. The solvent-excluded surface of (A) catalytic and (B) CWT lysostaphin domain was colored according to the sequence conservation determined using the Consurf server [55], with a set of sequences selected for analogous function and possibly diverse sequence (UniProt codes: H0DEX1, Q4L983, D3X7N2, FDP463, F7U55, F7U56, O05156, JGQV33, JGQX22, D6A2X0, Q99VV0, Q99X10, G5JF40, K9AV95, K0T1T9, K0U3K3 for catalytic domain; and D3X7N2, Q99VV0, O05156, H0DJE6, B9CV69, D3QFD1, J0JU31, H3UFO3, D4F197, D4L3Y5, H9A141, F9L879, E5C5C2, O56788 for the CWT domain). (C) Solvent-accessible surface of lysostaphin colored according to the electrostatic potential calculated with the DELPHI program [56]. The orientation in the top row is rotated 90° with respect the yellow/green molecule in Fig. 3 (and similar to Fig. 7A), the location of the putative substrate-binding grooves is marked by arrows.
on how the lysostaphin/Ale-1 family of CWT domains interacts with substrates is rather limited, as neither this work nor prior experiments with Ale-1 succeeded in crystallizing a CWT with bound substrate. Nevertheless, some informed speculation is possible. Based on a combination of structural studies, site-directed mutagenesis experiments and computational docking, amino acid residues of Ale-1 that affect peptidoglycan binding have been identified [20,34]. Because of the high sequence and structural similarity between the lysostaphin and Ale-1 CWT domains, the equivalent amino acids in the lysostaphin structure can be readily identified and located. Together, they indicate a relatively wide peptidoglycan-binding site, with notable...
enrichment of binding-related residues in the central groove of the domain (Fig. 7).

**Different linker conformations, domain mobility**

Comparison of the four lysostaphin molecules in the asymmetric unit of the crystals using the DynDom server [35] shows that they can be divided into pairs of molecules of very similar overall structure. However, between the pairs, there is major variation in the relative domain orientation, because of differences in the linker conformation around Gly388. The local differences in the linkers have drastic overall consequences. When CWT domains are superimposed, the catalytic domain orientations differ by ~100° and active sites are up to ~25 Å apart in each other (Fig. 3). The linker amino acid composition in lysostaphin (rich in glycines) classifies the linker as flexible [36]. Moreover, analysis of the amino acid conservation among lysostaphin and those homologues that share the architecture of N-terminal catalytic and C-terminal CWT domain reveals that the linker is among the least conserved regions of the proteins (conservation is even lower in the proregions).

Biochemical data suggest that domain mobility in solution exceeds the range observed in the crystal structure. Experimentally introduced cysteines in positions 332 (K332C) and 464 (T464C) can be cross-linked under oxidizing conditions [12], but the Cα carbon atoms of the mutated residues are >45 Å apart in all four molecules in the structure and cannot even be approximated by a simple closure or hinge between lysostaphin domains (Fig. 7A).

Possible interactions between the catalytic and CWT domains of lysostaphin were previously studied by comparing exposure to hydrogen/deuterium exchange between the full-length protein and its isolated domains [12]. In light of the structural data, the reported greater exposure of peptide 248–260 for the isolated domains is expected, because these residues are partly covered by the linker not included in the constructs for individual domains. Peptides 331–339 (on the surface of the catalytic domain) and 454–473 and 474–488 (in the CWT, partly in regular β-structure, but also containing surface exposed loops and edge strand fragments) are not in contact with the other domain in any of the four molecules in the crystal. Changes in their exposure to solvent between domains and full-length enzyme therefore require domain arrangements not observed in the structure, or alternatively ‘interdomain communication’ (Fig. 7A).

The above observations suggest that lysostaphin may anchor itself to peptidoglycan via its CWT domain, which could then cleave different interpeptides in the region, thus locally weakening peptidoglycan in a more effective way than by random cleavages throughout the polymer. The precise number of *S. aureus* interpeptide cross-bridges is unfortunately difficult to estimate, because the peptidoglycan structure is uncertain and because ‘parallel stem peptide’ models predict closer packing of cross-bridges than ‘antiparallel stem peptide’ models. We note that a modular architecture of peptidoglycan hydrolases is fairly common [37–40], particularly in phage from Gram-positive bacteria, which also need to keep lysis local [41,42]. The benefit from tethering a catalytic domain to a CWT domain is nicely illustrated by grafts of CWT domains to unrelated peptidoglycan hydrolases [43] and may at least in part explain the superiority of lysostaphin over LytM in *in vivo* applications.
**Experimental procedures**

**Protein purification**

The expression plasmid for lysostaphin (pET21) encoded the catalytic and CWT domains (residues 248–493, UniProt entry P10547) and a C-terminal His-tag (LEHHHHHHHHH sequence) under the control of the T7 promoter and lac repressor, as described previously [44]. BL21(DE3) *Escherichia coli* cells were grown in 2x YT media to a D_{600} of 0.6, induced with 1.2 mM isopropyl β-D-thiogalactoside, and grown for a further 3 h at 30 °C. The collected cells were harvested and the lysate was used for protein purification. The first purification step was performed on a Zn^{2+} column (5 mL Pharmacia HiTRAP chelating column charged with 50 mM ZnCl₂). The imidazole gradient was run from 0.5 mM to 1 M in 20 mM sodium phosphate pH 7.0, 0.5 M NaCl. Histidine-tagged lysostaphin eluted at 0.3–0.4 M imidazole. Gel filtration on a Sephacryl S100 column in 20 mM Tris/HCl pH 7.0, 0.5 M NaCl, 0.2 M imidazole was done as the final step of protein purification. After gel filtration, the protein sample was dialyzed against 20 mM Tris/HCl pH 7.0, 50 mM NaCl and concentrated.

The lysostaphin catalytic domain (residues 251–384) was cloned into the NcoI/XhoI site of a pET15b plasmid. The 134 amino acid peptide was overproduced in BL21 (DE3) *E. coli* in Luria–Bertani media by induction with 0.1 mM isopropyl β-D-thiogalactoside at 25 °C for 6 h. The cell pellet was suspended in 20 mM Tris/HCl pH 7.0, 1 M NaCl, 10% glycerol and disrupted by Constant Cell Disruption System (Constant Systems Ltd, Daventry, UK). Cell lysate was dialyzed against 20 mM Tris/HCl, pH 7.0, 50 mM NaCl and purified on SP Sepharose column (GE Healthcare, Uppsala, Sweden). The NaCl gradient was applied and the protein was eluted at ~0.9 M NaCl. Further purification was done by gel filtration on Superdex 75 column (GE Healthcare) in dialysis buffer.

**Crystallization**

All crystallization experiments were carried out by the vapor diffusion method in sitting drops at 4 °C. Mature lysostaphin was concentrated to 8 mg·mL⁻¹, and mixed in a 1 : 1 ratio with the reservoir buffer containing 0.1 M Mes/NaOH pH 6.5 and 1.6 M magnesium sulfate and 2 mM tetraglycine phosphinic acid. Drops were then equilibrated against the reservoir buffer. EDTA and ammonium sulfate as additives improved crystal quality. Prior to flash-cryocooling, the crystallization buffer was supplemented with 25% (v/v) glycerol. Lysostaphin crystals belonged to the cubic space group P4(3)32 and diffracted to 3.5–4 Å resolution at synchrotron beamlines.

Crystals of the catalytic domain of lysostaphin in the absence of phosphate were grown within a month by mixing an 11.5 mg·mL⁻¹ solution of the protein in a 1 : 1 ratio with reservoir buffer Morpheus 2-46 (Molecular Dimensions, Newmarket, UK). This buffer is composed of 0.1 M Tris (base), Bicine pH 8.5, 0.1 M amino acids [L-Na-glutamate, alanine (racemic), glycine; lysine-HCl (racemic); serine (racemic)], 30% v/v precipitant (ethylene glycol, PEG 8000). Crystals grew during a month of equilibration against the reservoir buffer. Crystals were flash-cooled directly from the drop. Thirty minutes prior to setting up the crystallization trials, the protein had been supplemented with 6 mM of the pentapeptide GGSGG, which should be resistant to lysostaphin cleavage because of the presence of the serine residue. However, there was no electron density for the pentapeptide found in the crystal.

Crystals of the catalytic domain of lysostaphin in the presence of phosphate were obtained by mixing the protein solution at a concentration of 11.5 mg·mL⁻¹ in a 1 : 1 ratio with the reservoir buffer Structure Screen 1–46 (Molecular Dimensions) containing 0.05 M potassium dihydrogen phosphate and 20% w/v PEG 8000. Similarly as in the absence of phosphates, the crystals grew within a month. Prior to flash-cryocooling, the crystallization buffer was supplemented with 10% (v/v) glycerol. Thirty minutes prior to setting up the crystallization trials, the protein had been supplemented with 6 mM glycine hydroxamate. Crystals were soaked for 5 min with 25 mM iodo-GGSGG pentapeptide dissolved in the buffer used for cryocooling, but no electron density for the putative inhibitors was observed.

**Structure determination**

The crystals of the full-length lysostaphin were tested on multiple beamlines (of DIAMOND, ELETTRA, PETRA and BESSY) aiming at the highest possible data quality. The best dataset was collected on the MX 14.1 beamline of BESSY at a wavelength of 0.9184 Å. Two wavelength MAD data that have been used for phasing were collected on DIAMOND IO2 beamline to 4.0 Å. The two final datasets for the lysostaphin catalytic domain were collected at MX 14.1 (1.26 Å) and 14.2 (1.78 Å). All diffraction data were processed using the xds suite [45].

The full-length lysostaphin structure was solved by a combination of the molecular replacement (MR) and the MAD methods. Careful preparation of the search models proved crucial. Multiple structure-based sequence alignments were generated for the homologues of the catalytic and CWT domains of lysostaphin, using the DALI sever [46]. The alignments revealed potential flexible loop regions (indicated by high rmsd values and high crystallographic temperature factors), which were deleted for the MR search. Finally, the structures of *S. aureus* LytM (PDB ID 2BOP, chain A [19]) and *S. capitis* Ale-1 (1R77, chain A [20]) were chosen as search models based on the low overall temperature factors and high resolution. A sequential MR search scheme was carried out using Phaser [47]. The first
three copies of the truncated LytM search model were placed correctly with high log likelihood gain values. Placement of three copies of truncated Ale-1 in subsequent MR search steps raised the log likelihood gain value of the solution to over 1000. Placement of further molecules by MR failed. Therefore, a two-wavelength MAD experiment (peak wavelength 1.2827 Å and inflection wavelength 1.2831 Å) was performed to obtain experimental phases. Zn$^{2+}$-binding sites were located in the anomalous difference Fourier map calculated with peak wavelength diffraction data and model phases. Altogether, only four Zn$^{2+}$ ions were found, strongly suggesting that the crystals contained four molecules of lysostaphin in the asymmetric unit. The programs SHARP [48] and SOLOMON [49] were used to calculate an experimental electron-density map, which was very clear even without noncrystallographic symmetry averaging. The two missing domains (one catalytic and one CWT) were tentatively built by manual density interpretation. Electron density was then cut out in their vicinity and used for additional real-space MOLREP [50] searches using the models of the catalytic and CWT domains. The linkers between cell wall and catalytic domain were built manually with the COOT program [51]. Register errors are very unlikely in the globular domains and the better defined parts of the linkers. In all four cases, the electron density is of sufficient quality to decide with confidence which catalytic and CWT domains are covalently linked. In the most ill-defined regions of the linkers, Ramachandran indicators suggest that the model is poorer than elsewhere, and we cannot exclude register errors. Refinement of the mature lysostaphin was carried out in REFMAC [52] with separate noncrystallographic symmetry restraints for CWT (residues 403–493) and catalytic (residues 278–385) domains, but no noncrystallographic symmetry restraints for the linkers (386–402). The model was refined to the final $R$-factors of $R_{\text{cryst}} = 27.8\%$ and $R_{\text{free}} = 29.6\%$. Geometry indicators of the model were typical of structures at this resolution (rmsd bond lengths = 0.012 Å, rmsd angles = 1.4°, 99.3% of residues in the allowed region of the Ramachandran plot).

The crystals of the lysostaphin catalytic domain had a nearly orthorhombic lattice. However, scaling of the diffraction data indicated that the crystals were only monoclinic. Extinctions on the axis of symmetry identified the space group as P2(1). An analysis of the solvent content suggested the presence of two catalytic domains in the crystallographic asymmetric unit. The crystal grown in the presence of phosphate showed clear indications of twinning and thus test reflections were selected in thin resolution shells. The structure was solved by MR with the help of the catalytic domain of the mature enzyme. The model was rebuilt automatically with the ARP/WARP program [53]. The structure was refined with PHENIX [54] in the twin refinement mode, which reduced the $R$ factors by ~7%. The crystal grown in the absence of phosphate was solved with MR using the refined catalytic domain structure as a model. The test reflections were chosen consistently. The crystal was did not appear to be significantly twinned, as judged by XTRIAGE [54], therefore the refinement was carried out in the standard mode in REFMAC [52]. Data collection and refinement statistics are presented in Table 1. The atomic coordinates and corresponding structure factors have been deposited at PDB with the following accession codes: full-length lysostaphin, 4LXC; catalytic domain in the presence of the phosphate, 4QP5; and in its absence, 4PQB.

Acknowledgements

We are grateful for access to the IO2 beamline at DLS, Harwell UK, the XRD1 beamline at Elettra, Trieste, Italy, the 14.1 and 14.2 beamlines at BESSY, Berlin and the BW6 beamline at DESY, Hamburg Germany. We are thankful to Drs M. Nowotny and E. Nowak for help in data collection. PTB and JAS acknowledge funding from the MRC (UK). This work was supported by NCBiR grant (PBS1/A8/8/2012) (PL).

Author contributions

IS planned experiments, performed experiments, analyzed data and wrote the paper. EJ performed experiments and analyzed data. PTB planned experiments, performed experiments, and contributed reagents or other essential material. HC performed experiments and analyzed data. SOD analyzed data. JAS contributed reagents or other essential material. RJ planned experiments. MET analyzed data. NRT planned experiments. MB planned experiments, analyzed data and wrote the paper.

References

1 van Hal SJ, Jensen SO, Vaska VL, Espedido BA, Paterson DL & Gosbell IB (2012) Predictors of mortality in Staphylococcus aureus bacteremia. Clin Microbiol Rev 25, 362–386.
2 Schindler CA & Schuhardt VT (1965) Purification and properties of lysostaphin – a lytic agent for Staphylococcus aureus. Biochim Biophys Acta 97, 242–250.
3 Schindler CA & Schuhardt VT (1964) Lysostaphin: a new bacteriolytic agent for Staphylococcus. Proc Natl Acad Sci USA 51, 414–421.
4 Schuhardt VT & Schindler CA (1964) Lysostaphin therapy in mice infected with Staphylococcus aureus. J Bacteriol 88, 815–816.
5 Kokai-Kun JF, Chanturiya T & Mond JJ (2009) Lysostaphin eradicates established
**Staphylococcus aureus** biofilms in jugular vein catheterized mice. *J Antimicrob Chemother* **64**, 94–100.

6 Kokai-Kun JF, Chanturiya T & Mond JJ (2007) Lysostaphin as a treatment for systemic *Staphylococcus aureus* infection in a mouse model. *J Antimicrob Chemother* **60**, 1051–1059.

7 Kerr DE, Plaut K, Bramley AJ, Williamson CM, Lax AJ, Moore K, Wells KD & Wall RJ (2001) Lysostaphin expression in mammary glands confers protection against staphylococcal infection in transgenic mice. *Nat Biotechnol* **19**, 66–70.

8 Donovan DM, Kerr DE & Wall RJ (2005) Engineering disease resistant cattle. *Transgenic Res* **14**, 563–567.

9 Fan W, Plaut K, Bramley AJ, Barlow JW & Kerr DE (2002) Adenoviral-mediated transfer of a lysostaphin gene into the goat mammary gland. *J Dairy Sci* **85**, 1709–1716.

10 Fan W, Plaut K, Bramley AJ, Barlow JW, Mischler SA & Kerr DE (2004) Persistence of adenoviral-mediated lysostaphin expression in goat mammary glands. *J Dairy Sci* **87**, 602–608.

11 Climo MW, Patron RL, Goldstein BP & Archer GL (1998) Lysostaphin treatment of experimental methicillin-resistant *Staphylococcus aureus* aortic valve endocarditis. *Antimicrob Agents Chemother* **42**, 1355–1360.

12 Lu HR, Gu MG, Huang Q, Huang JJ, Lu WY, Lu H & Huang QS (2013) Hydrogen/deuterium exchange mass spectrometry and site-directed disulfide cross-linking suggest an important dynamic interface between the two lysostaphin domains. *Antimicrob Agents Chemother* **57**, 1872–1881.

13 Kluytmans J, van Belkum A & Verbrugh H (1997) Nasal carriage of *Staphylococcus aureus*: epidemiology, underlying mechanisms, and associated risks. *Clin Microbiol Rev* **10**, 505–520.

14 Wu JA, Kusuma C, Mond JJ & Kokai-Kun JF (2003) Lysostaphin disrupts *Staphylococcus aureus* and *Staphylococcus epidermidis* biofilms on artificial surfaces. *Antimicrob Agents Chemother* **47**, 3407–3414.

15 Shah A, Mond J & Walsh S (2004) Lysostaphin-coated catheters eradicate *Staphylococcus aureus* challenge and block surface colonization. *Antimicrob Agents Chemother* **48**, 2704–2707.

16 Thumm G & Gotz F (1997) Studies on polypeptides processing and characterization of the lysostaphin immunity factor (Lif) of *Staphylococcus simulans* biovar *staphylohyicus*. *Mol Microbiol* **23**, 1251–1265.

17 Schneewind O, Fowler A & Faull KF (1995) Structure of the cell wall anchor of surface proteins in *Staphylococcus aureus*. *Science* **268**, 103–106.

18 Odintsov SG, Sabala I, Marcyjaniak M & Bochtler M (2004) Latent LytM at 1.3 Å resolution. *J Mol Biol* **335**, 775–785.

19 Firczuk M, Mucha A & Bochtler M (2005) Crystal structures of active LytM. *J Mol Biol* **354**, 578–590.

20 Lu JZ, Fujiwara T, Komatsuzawa H, Sugai M & Sakon J (2006) Cell wall-targeting domain of glycyglycine endopeptidase distinguishes among peptidoglycan cross-bridges. *J Biol Chem* **281**, 549–558.

21 Spencer J, Murphy LM, Conners R, Sessions RB & Gamblin SJ (2010) Crystal structure of the LasA virulence factor from *Pseudomonas aeruginosa*: substrate specificity and mechanism of M23 metallopeptidases. *J Mol Biol* **396**, 908–923.

22 Sabala I, Jonsson IM, Tarkowski A & Bochtler M (2012) Anti-staphylococcal activities of lysostaphin and LytM catalytic domain. *BMC Microbiol* **12**, 97.

23 Climo MW, Ehlert K & Archer GL (2001) Mechanism and suppression of lysostaphin resistance in oxacillin-resistant *Staphylococcus aureus*. *Antimicrob Agents Chemother* **45**, 1431–1437.

24 Trayer HR & Buckley CE 3rd (1970) Molecular properties of lysostaphin, a bacteriolysin agent specific for *Staphylococcus aureus*. *J Biol Chem* **245**, 4842–4846.

25 Lagarias JC, Hales TC & Ferguson S (2011) The Kepler Conjecture: The Hales-Ferguson Proof by Thomas Hales, Samuel Ferguson. Springer, New York.

26 Yeates TO & Fam BC (1999) Protein crystals and their evil twins. *Structure* **7**, R25–R29.

27 Bochtler M, Odintsov SG, Marcyjaniak M & Sabala I (2004) Similar active sites in lysostaphins and α-Ala–α-Ala metallopeptidases. *Protein Sci* **13**, 854–861.

28 Harding MM (2000) The geometry of metal–ligand interactions relevant to proteins. II. Angles at the metal atom, additional weak metal–donor interactions. *Acta Crystallogr D* **56**, 857–867.

29 Rawlings ND, Morton FR, Kok CY, Kong J & Barrett AJ (2008) MEROPS: the peptidase database. *Nucleic Acids Res* **36**, D320–D325.

30 Pavlov M, Siegbahn PEM & Sandstroem M (1998) Hydration of beryllium, magnesium, calcium and zinc ions using density functional theory. *J Phys Chem A* **102**, 219–228.

31 Blumberger J, Lamoureux G & Klein ML (2007) Peptide hydrolysis in thermolysin: *ab initio* QM/MM investigation of the Glu-143 assisted water addition mechanism. *J Chem Theory Comput* **3**, 1837–1850.

32 Grundling A & Schneewind O (2006) Cross-linked peptidoglycan mediates lysostaphin binding to the cell wall envelope of *Staphylococcus aureus*. *J Bacteriol* **188**, 2463–2472.

33 Becker SC, Foster-Frej J, Stodola AJ, Anacker D & Donovan DM (2009) Differentially conserved staphylococcal SH3b_5 cell wall binding domains confer increased staphyloytic and streptolytic activity to a streptococcal prophage endolysin domain. *Gene* **443**, 32–41.

34 Hirakawa H, Akita H, Fujiwara T, Sugai M & Kuhara S (2009) Structural insight into the binding mode
between the targeting domain of Ale-1 (92AA) and pentaglycine of peptidoglycan. *Protein Eng Des Sel* **22**, 385–391.

35 Hayward S & Berendsen HJ (1998) Systematic analysis of domain motions in proteins from conformational change: new results on citrate synthase and T4 lysozyme. *Proteins* **30**, 144–154.

36 Chen X, Zaro JL & Shen WC (2013) Fusion protein linkers: property, design and functionality. *Adv Drug Deliv Rev* **65**, 1357–1369.

37 Hermoso JA, Monterroso B, Albert A, Galan B, Ahrazem O, Garcia P, Martinez-Ripoll M, Garcia JL & Menendez M (2003) Structural basis for selective recognition of pneumococcal cell wall by modular endolysin from phage Cp-1. *Structure* **11**, 1239–1249.

38 Korndorfer IP, Danzer J, Schmelcher M, Zimmer M, Xu Q, Chiu HJ, Farr CL, Jaroszewski L, Knuth MW, Nelson DC, Schmelcher M, Rodriguez-Rubio L, Skerra A, Mallreck J, Langer G, Cohen SX, Lamzin VS & Perrakis A (2008) Structures of a bifunctional cell wall hydrolase CwIT containing a novel bacterial lysozyme and an NlpC/P60 ω-endoropeptidase. *J Mol Biol* **426**, 678–689.

39 Xu Q, Chiu HJ, Farr CL, Jaroszewski L, Knuth MW, Miller MD, Lesley SA, Godzik A, Elsliger MA, Deacon AM et al. (2013) Structures of a novel endolysin encoded by episomal phage phiSM101 of Clostridium perfringens. *Mol Microbiol* **92**, 326–337.

40 Tamai E, Yoshida H, Sekiya H, Nariya H, Miyata S, Okabe A, Kuwahara T, Maki J & Kamitori S (2014) X-Ray structure of a novel endolysin revealed by symmetry. *Acta Crystallogr D* **66**, 213–226.

41 Nelson DC, Schmelcher M, Rodriguez-Rubio L, Klumpp J, Pritchard DG, Dong S & Donovan DM (2012) Endolysins as antimicrobials. *Adv Virus Res* **83**, 299–365.

42 Schmelcher M, Donovan DM & Loessner MJ (2012) Bacteriophage endolysins as novel antimicrobials. *Future Microbiol* **7**, 1147–1171.

43 Schmelcher M, Powell AM, Becker SC, Camp MJ & Donovan DM (2012) Chimeric phage lysins act synergistically with lysoptaphin to kill staphilolin causing *Staphylococcus aureus* in murine mammary glands. *Appl Environ Microbiol* **78**, 2297–2305.

44 Bardelang P, Vankemmelbeke M, Zhang Y, Jarvis H, Antoniadou E, Rochette S, Thomas NR, Penfold CN & James R (2009) Design of a polypeptide FRET substrate that facilitates study of the antimicrobial protease lyostaphin. *Biochem J* **418**, 615–624.

45 Kabsch W (2010) Xds. *Acta Crystallogr D* **66**, 125–132.

46 Holm L & Rosenstrom P (2010) Dali server: conservation mapping in 3D. *Nucleic Acids Res* **38**, W545–W549.

47 McCoy AJ, Grosse-Kunstleve RW, Adams PD, Winn MD, Storoni LC & Read RJ (2007) Phaser crystallographic software. *J Appl Crystallogr* **40**, 658–674.

48 Bricogne G, Vonrhein C, Flensburg C, Schiltz M & Paciorek W (2003) Generation, representation and flow of phase information in structure determination: recent developments in and around SHARP 2.0. *Acta Crystallogr D* **59**, 2023–2030.

49 Abrahams JP & Leslie AG (1996) Methods used in the structure determination of bovine mitochondrial F1 ATPase. *Acta Crystallogr D* **52**, 30–42.

50 Vagin A & Teplyakov A (2010) Molecular replacement with MOLREP. *Acta Crystallogr D* **66**, 22–25.

51 Emsley P, Lohkamp B, Scott WG & Cowtan K (2010) Features and development of Coot. *Acta Crystallogr D* **66**, 486–501.

52 Murshudov GN, Vagin AA & Dodson EJ (1997) Refinement of macromolecular structures by the maximum-likelihood method. *Acta Crystallogr D* **53**, 240–255.

53 Langer G, Cohen SX, Lamzin VS & Perrakis A (2008) Automated macromolecular model building for X-ray crystallography using ARP/wARP version 7. *Nat Protoc* **3**, 1171–1179.

54 Adams PD, Afonine PV, Bunkoczi G, Chen VB, Davis IW, Echols N, Headd JJ, Hung LW, Kapral GJ, Grosse-Kunstleve RW et al. (2010) PHENIX: a comprehensive Python-based system for macromolecular structure solution. *Acta Crystallogr D* **66**, 213–221.

55 Celniker G, Nimrod G, Aszkenazy H, Glaser F, Martz E, Mayrose I, Pupko T & Ben-Tal N (2013) ConSurf: using evolutionary data to raise testable hypotheses about protein function. *Israel J Chem* **153**, 199–206.

56 Li L, Li C, Sarkar S, Zhang J, Witham S, Zhang Z, Wang L, Smith N, Petukh M & Alexov E (2012) DelPhi: a comprehensive suite for DelPhi software and associated resources. *BMC Biophys* **5**, 9.